Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Omega 3: Ischemic Heart Disease - Nutraceuticals World

What are you searching for?

Sign in
Research

Omega 3: Ischemic Heart Disease

Author Image

By: Sean Moloughney

Editor, Nutraceuticals World

Nutraceutical: Omega 3
 
Indication: Ischemic heart disease (IHD)
 
Source: Am J Clin Nutr, Aug 24, 2011 [Epub ahead of print].
 
Research: n-3 (omega 3) PUFA has been proposed as having health-promoting effects, primarily in relation to ischemic heart disease (IHD). Whether these benefits can be achieved by both alpha linolenic acid* (ALA, 18:3n-3) and n-3 long-chain PUFA (LC-PUFA) is debatable, according to researchers. The objective of this study was to examine the association between ALA intake and risk of IHD in healthy subjects and to see if this was modified by intake of n-3 LC-PUFA or linoleic acid (LA, 18:2 n-6). Four hundred seventy-one cases of IHD were observed during a median follow-up period of 23 years.
 
Results: Higher intake of ALA was not significantly associated with decreased risk of IHD among women or men. However, high n-3 LC-PUFA intake, in comparison with low intake, was inversely associated with risk of IHD; this trend was significant in women but not in men. No associations were observed between intake of LA and risk of IHD.

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Add Nutraceuticals World as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters

Topics